The DPP-4 inhibitors were also examined as add-on to on-going metformin in subjects with type 2 diabetes in 24–26 week studies with a total number of 3,216 subjects [Table 2; (71–75)]. Here, DPP4 is linked to type 2 diabetes mellitus.